In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
US pharma giant Pfizer has presented its financial results for the fourth quarter and full year of 2023. 30 January 2024
Pharmaceutical
Vertex Pharmaceuticals today announced positive results from its Phase III program for the selective non-opioid selective NaV1.8 inhibitor V VX-548, in the treatment of moderate-to-severe acute pain. 30 January 2024
Pharmaceutical
Indian drugmaker Orchid Pharma's antibiotic drug Exblifep (cefepime/enmetazobactam) has received approval from the European Medicines Agency (EMA), leading to a 20% surge in the company's stock. 30 January 2024
Biotechnology
Danish biotech Ascendis Pharma today announced the formation and launch with Frazier Life Sciences of Eyconis Inc, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. 30 January 2024
Biotechnology
Britain’s medicines regulator has approved a novel antibiotic developed by Cidara Therapeutics, a biotechnology company based in San Diego, California. 30 January 2024
Biotechnology
US precision genetic medicines firm Sarepta Therapeutics has announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase II, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that enrolled patients aged eight to 21 years. 30 January 2024
Biotechnology
Two Californian firms, Gilead Sciences and Arcus Biosciences, have doubled down on their commitment to developing new therapies using the TIGIT pathway. 30 January 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a significant breakthrough in targeted cancer therapy. 30 January 2024
Biotechnology
Enterprise Therapeutics, a UK biopharma dedicated to the discovery and development of novel therapies for respiratory disease, has closed a £26 million ($33.1 million) Series B follow-on financing round, led by Panakes Partners. 30 January 2024
article
Following on from its recent approval of Hyqvia (immune globulin) in Europe, Japanese pharma major Takeda has picked up a US approval for another CIDP product. 30 January 2024
Biotechnology
Industry observers are cautiously hoping that early 2024 signs indicate that the post-pandemic biotech fundraising slowdown might be coming to an end. 30 January 2024
Biosimilars
Iceland-based developer of biosimilar medicines, Alvotech has announced positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to US biotech major Amgen’s Prolia and Xgeva, with both having the active ingredient denosumab at different dosages. 30 January 2024
Pharmaceutical
Having first authorized US pharma giant Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir and ritonavir) for emergency use, the US Food and Drug Administration (FDA) is now making another amendment. 30 January 2024
Biotechnology
Austrian arenaviral technology firm Hookipa Pharma yesterday announced a reprioritization, after it received a notification from Swiss pharma giant Roche that it has decided to terminate their collaboration. 30 January 2024
Pharmaceutical
Takeda has secured European approval for Hyqvia (immune globulin) as maintenance therapy for people with chronic inflammatory demyelinating polyneuropathy (CIDP). 29 January 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. 29 January 2024
Biotechnology
California, USA-based Skye Bioscience’s shares edged up 2.4% to $2.38 in early trading, as it announced a $50.25 million private placement equity financing. 29 January 2024
Pharmaceutical
American biotech Exelixis and French partner Ipsen have announced detailed results from the Phase III CONTACT-02 trial. 29 January 2024
Biotechnology
The global messenger ribonucleic acid (mRNA) vaccine market currently consists entirely of vaccines for COVID-19. The rapid sequencing of the SARS-CoV-2 viral genome and the subsequent development of these jabs in response to the pandemic led to the authorization of the first of these vaccines in December 2020. 29 January 2024
Biotechnology
The US supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review for patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or who have no satisfactory alternative treatment options. 29 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze